Jonathan Aschoff
Stock Analyst at Roth MKM
(0.54)
# 3,833
Out of 4,784 analysts
43
Total ratings
21.15%
Success rate
-34.47%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GTBP GT Biopharma | Initiates: Buy | $11 | $2.40 | +358.33% | 1 | Dec 2, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $7.85 | +167.52% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $555 → $296 | $1.12 | +26,328.57% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $1.81 | +894.48% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $17 | $0.98 | +1,643.23% | 2 | Aug 13, 2024 | |
| OTRK Ontrak | Maintains: Buy | $60 → $45 | $1.48 | +2,940.54% | 2 | Aug 9, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $20 | $1.11 | +1,701.80% | 1 | Jul 16, 2024 | |
| CYCC Cyclacel Pharmaceuticals | Maintains: Buy | $21 → $11 | $0.30 | +3,578.93% | 2 | May 3, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $40 | $1.04 | +3,746.15% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $20 → $28 | $0.33 | +8,263.20% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $36 | $6.19 | +481.58% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $24 | $0.42 | +5,614.29% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $6.49 | +362.25% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $3.22 | +6,111.18% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $1.70 | +723.53% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $2,400 → $7,200 | $2.70 | +266,566.67% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $0.80 | +900.63% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $2.27 | +4,305.29% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.81 | +49,100.49% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $3.31 | +1,048.04% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24,000 | $1.76 | +1,363,536.36% | 1 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $1.73 | +5,449.13% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $7.52 | +72.87% | 1 | Dec 19, 2019 |
GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $2.40
Upside: +358.33%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $7.85
Upside: +167.52%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $555 → $296
Current: $1.12
Upside: +26,328.57%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $1.81
Upside: +894.48%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $17
Current: $0.98
Upside: +1,643.23%
Ontrak
Aug 9, 2024
Maintains: Buy
Price Target: $60 → $45
Current: $1.48
Upside: +2,940.54%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $20
Current: $1.11
Upside: +1,701.80%
Cyclacel Pharmaceuticals
May 3, 2024
Maintains: Buy
Price Target: $21 → $11
Current: $0.30
Upside: +3,578.93%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $1.04
Upside: +3,746.15%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $20 → $28
Current: $0.33
Upside: +8,263.20%
Mar 7, 2024
Maintains: Buy
Price Target: $25 → $36
Current: $6.19
Upside: +481.58%
Mar 5, 2024
Maintains: Buy
Price Target: $5 → $24
Current: $0.42
Upside: +5,614.29%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $6.49
Upside: +362.25%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $3.22
Upside: +6,111.18%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $1.70
Upside: +723.53%
Feb 14, 2023
Maintains: Buy
Price Target: $2,400 → $7,200
Current: $2.70
Upside: +266,566.67%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $0.80
Upside: +900.63%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $2.27
Upside: +4,305.29%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $0.81
Upside: +49,100.49%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $3.31
Upside: +1,048.04%
Feb 12, 2021
Initiates: Buy
Price Target: $24,000
Current: $1.76
Upside: +1,363,536.36%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $1.73
Upside: +5,449.13%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $7.52
Upside: +72.87%